Feasibility Study to Assess the Safety and Functionality of the GluSense Continuous Glucose Monitor in Diabetic Patients

Phase 1

Completed

• Conditions: Diabetes

• Registration Number: NCT01198678
• Lead Sponsor: GluSense Ltd

Brief Summary

Currently marketed CGM sensors have an approved functional lifetime of up to 1 week. Pre-clinical studies have demonstrated that GluSense-LTone 2e3 sensors may be used to accurately monitor glucose levels for 30 days. The purpose of this study is to assess the safety and functionality of the device in human patients for consecutive 15 days.

GluSense-LTone 2e3 as long term CGM, will require less sensor replacements and calibration, meaning less patient interventions, and is therefore will be much more user friendly. Moreover, GluSense-LTone 2e3 shows potentially increased accuracy, especially in the critically important hypoglycemic range, meaning that better management of patient's condition may be attained.

Detailed Description

GluSense-LTone 2e3 is a continuous glucose monitoring (CGM) system. It is a semi-invasive, optical fiber-based device with a lifetime of up to one month. The purpose of this study is to assess the safety, accuracy, calibration requirements and effective lifetime of the device.

Study Timeline

• Study First Submitted: 2010-09-08
• Study First Submitted QC: 2010-09-09
• Study First Posted: 2010-09-10
• Study Start: 2010-11
• Status Verified: 2010-12
• Primary Completion: 2011-01
• Study Completion: 2011-02
• Last Update Submitted: 2011-03-29
• Last Update Posted: 2011-03-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Patients must meet all of the following inclusion criteria to be eligible for participation in this study:

• Male or female patients between 18 and 50 years of age
• Patients with type 1 diabetes mellitus.
• The ability to read, understand and sign an informed consent form. Written consent must be obtained prior to initiation of study procedures

Exclusion Criteria

Patients who meet any of the following exclusion criteria are not to be enrolled in this study:

• Clinical significant illness that can compromise patient's health during study such as:

  • Significant current heart disease
  • Significant Liver or kidney disease
  • HIV infection
  • Hepatitis B or Hepatitis C infection
  • Malignancy
  • Major allergic skin disease including plaster allergies
  • Significant allergic disorders

• Current or recent significant skin conditions (e.g. eczema, psoriasis,).

• Presence of skin markings/ abnormalities around implantation site that will interfere with the skin assessment e.g. tattoos, piercings, birthmark, sunburn

• Current alcohol or substance use judged by the IP to potentially interfere with patient study compliance.

• Routine administration of Steroid based medications.

• Patients currently taking part in any other clinical trial using an investigational product within the last 3 months

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Evaluate capability to follow glucose concentration changes over 15 consecutive days	3 weeks

Trial Locations

Locations (1)

University medical Center Ljubljana; 🇸🇮 Ljubljana, Slovenia